HERMANCE FRANK S
Known title: DirectorCIK: 0001190203
HERMANCE FRANK S's purchase track record
HERMANCE FRANK S has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 2/16/2022 | UGI | $2.48M | +6.3% | +12.5% | -4.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| UGI | ▲ Buy | Grant | 4,640 | $0 | 1/27/2023 | View on chart |
| UGI | ▲ Buy | Option Exercise | 12,750 | $282K | 12/1/2022 | View on chart |
| UGI | ▼ Sell | Open Market | 12,750 | $495K | 12/1/2022 | View on chart |
| UGI | ▲ Buy | Open Market | 65,000 | $2.5M | 2/16/2022 | View on chart |
| UGI | ▲ Buy | Grant | 10,810 | $0 | 1/28/2022 | View on chart |
| UGI | ▲ Buy | Option Exercise | 12,750 | $240K | 11/23/2021 | View on chart |
| UGI | ▼ Sell | Open Market | 12,750 | $573K | 11/23/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Scotiabank initiates UGI coverage with Sector Outperform rating
Scotiabank began tracking UGI with a Sector Outperform rating and a $46 price target. This follows a regulatory decision allowing phased gas rate increases while blocking a base-rate filing until 2029. The new analyst view provides a fresh perspective on the utility's valuation and regulatory outlook.
Scotiabank initiates UGI coverage with Sector Outperform rating. Scotiabank began tracking UGI with a Sector Outperform rating and a $46 price target. This follows a regulatory decision allowing phased gas rate increases while blocking a base-rate filing until 2029. The new analyst view provides a fresh perspective on the utility's valuation and regulatory outlook.